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Abstract
Purpose: Magnetic resonance image guided radiation therapy (MR-IGRT) has been used at our
institution since 2014. We report on more than 2 years of clinical experience in treating patients
with the world’s ﬁrst MR-IGRT system.
Methods and materials: A clinical service was opened for MR-IGRT in January 2014 with an
MR-IGRT system consisting of a split 0.35T magnetic resonance scanner that straddles a ring
gantry with 3 multileaf collimator-equipped 60Co heads. The service was expanded to include
online adaptive radiation therapy (ART) MR-IGRT and cine gating after 6 and 9 months,
respectively. Patients selected for MR-IGRT were enrolled in a prospective registry between
January 2014 and June 2016. Patients were treated with a variety of radiation therapy
techniques including intensity modulated radiation therapy and stereotactic body radiation
therapy (SBRT). When applicable, online ART was performed and gating on sagittal
2-dimensional cine MR was used. The charts of patients treated with MR-IGRT were reviewed
to report on the clinical and treatment characteristics of the initial patients who were treated
with this novel technique.
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Results: A total of 316 patients have been treated with the MR-IGRT system, which has been
integrated into a high-volume clinic. The cases were most commonly selected for improved soft
tissue visualization, ART, and cine gating. Seventy-six patients were treated with 3-dimensional
conformal radiation therapy, 146 patients with intensity modulated radiation therapy, and 94
patients with SBRT. The most commonly treated disease sites were the abdomen (28%), breast
(26%), pelvis (22%), thorax (19%), and head and neck (5%). Sixty-seven patients were treated with
online ART over a total of 244 adapted fractions. Cine treatment gating was used for a total of 81
patients.
Conclusions: MR-IGRT has been successfully implemented in a high-volume radiation clinic and
provides unique advantages in the treatment of a variety of malignancies. Additional clinical trials
are in development to formally evaluate MR-IGRT in the treatment of multiple disease sites with
techniques such as SBRT and ART.
ª 2017 the Authors. Published by Elsevier Inc. on behalf of the American Society for Radiation
Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Magnetic resonance (MR) image guided radiation
therapy (IGRT) represents a treatment modality that offers
potential solutions to the well-recognized challenges of
radiation delivery. Compared with computed tomography
(CT)-based strategies, MR imaging (MRI) for treatment
guidance offers superior soft tissue deﬁnition that is
potentially advantageous in numerous disease sites.1
From a patient-safety perspective, daily image guidance
with MR also avoids undesirable radiation exposure
inherent to the use of CT imaging guidance such as cone
beam CT (CBCT). Moreover, cine MRI can be safely
employed throughout a patient’s entire treatment fraction
and course to monitor and manage intrafraction motion.
MR-IGRT enables daily imaging of sufﬁcient quality to
permit daily plan adjustments in response to interfraction
changes in anatomy.2 This approach is valid even in
disease sites that are typically poorly visualized with
conventional x-ray imaging, such as soft tissues within
the abdomen and pelvis.1 This daily plan adjustment,
termed online adaptive radiation therapy (ART), has been
found in dosimetric studies to potentially improve the
therapeutic ratio of radiation therapy (RT) by enhanced
sparing of organs-at-risk (OARs) and safe-dose escalation
in disease sites where high-dose therapy has been
limited.3,4 Thus, MR-IGRT has the potential to improve
the accuracy, precision, and safety of RT delivery.
Historically, MR-IGRT has been unavailable due to
the challenges of protecting a radiation delivery device
from the inﬂuence of a magnetic ﬁeld and maintaining
imaging quality in the presence of a treatment device. At
our institution, the world’s ﬁrst commercially available
device for MR-IGRT was clinically developed and
implemented in routine clinical practice (MRIdian Sys-
tem; ViewRay Inc., Oakwood Village, OH). In the more
than 2 years after the ﬁrst patient treatment in January
2014, more than 300 patients have been treated in disease
sites such as head and neck, breast, thorax, abdomen, and
pelvis. In this study, we review our institutional experi-
ence with patients who were treated on the world’s ﬁrst
MR-IGRT system. More speciﬁcally, we aim to describe
our initial clinical experience and the integration of this
new technology within a high-volume clinical practice,
highlight the technical capabilities of the system, and




The radiation oncology department at our institution
includes 21 attending radiation oncologists who service
our main site and 5 additional satellite locations. The main
facility includes 7 linear accelerators with a dedicated MR
simulator, a Gamma Knife Perfexion (Elekta, Stockholm,
Sweden), a single-gantry proton therapy system (Mevion,
Littleton, MA), a cobalt 60-based MR-IGRT system
(ViewRay Inc., Oakwood Village, OH), and a full
brachytherapy suite. A linear acceleratorebased
MR-IGRT system is currently under construction. Our
satellite facilities have an additional 7 linear accelerators.
In 2015, approximately 3,400 patients were treated with
external beam radiation therapy at our facility.5
All patients included in this study were enrolled in an
institutional review boardeapproved prospective registry,
and informed written consent for treatment was obtained.
Patients were divided into groups on the basis of the
anatomical site of the malignancy and the treatment
technique (stereotactic body radiation therapy [SBRT],
adaptive, gating). Additionally, the clinical rationale with
regard to the selection of MR-IGRT compared with
conventional linac-based treatment was evaluated
(ie, improved soft tissue imaging, cine gating on the basis
of daily anatomy, and online/ofﬂine adaptation) when
available.
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Magnetic resonance image guided radiation
therapy system
A complete description of the system and treatment
workﬂow has been previously described.6,7 Brieﬂy, the
MR-IGRT system comprises open, split-solenoid low-
ﬁeld magnetic resonance imaging (MRI) and a 60Co ra-
diation delivery device. The MRI has a ﬁeld strength of
0.35T, and the RT delivery system includes a robotic
3-headed 60Co device with a nominal dose rate of 550
cGy/min from three 27.3  27.3 cm2 ﬁelds to the 105 cm
isocenter.6
Simulation and planning
All patients underwent CT simulation, as well as MR
simulation when applicable, per our institutional protocol
and based on the site being treated. The CT planning
simulation (Philips Brilliance Small Bore, Philips Medical
System, Andover, MA) was planned to the emulate pa-
tient set-up that would occur during MR-IGRT. The MR
simulation process included a high-resolution, volumetric
MRI, followed by planar cine MR in the sagittal plane to
evaluate target motion characteristics if necessary for
planning purposes. The entire simulation procedure is
approximately 1.5 hours in duration.
The MR-IGRT system has a dedicated treatment
planning system (TPS). Although the TPS has image
registration and contouring capabilities, following our
standard clinic workﬂow CT and MR simulation images
were transferred to a third-party software for contouring
and then transferred to the MR-IGRT TPS for plan cre-
ation. The TPS is capable of conformal and intensity
modulated radiation therapy (IMRT) planning and uses a
fast Monte Carlo dose calculation algorithm.
On treatment days, patients were screened for MRI
contraindication. Once in the treatment room, they were
positioned and aligned to marks that were placed during
CT simulation. Either an end-exhale breath hold or a free-
breathing, volumetric MRI image then was acquired.
When applicable, a clinical gross target volume (GTV) or
GTV delineation was conﬁrmed or manually recontoured
at the MR-IGRT console to obtain a 2-dimensional MRI
(cine) view of the target for gating on the treatment ma-
chine during MR simulation.
Online adaptive radiation therapy
Our institutional workﬂow has been described in a
previous study for patients who were treated with online
ART.2 Brieﬂy, all patients underwent simulation with
pretreatment planning as described previously. At the
time of the ﬁrst treatment fraction, all patients underwent
a 17- or 25-second volumetric setup MRI at exhale breath
hold with an in-plane resolution of 1.67 mm and a 3.0 mm
slice thickness. The patient was localized to the target for
maximal target overlap, and the electron density map and
planning contours were transferred to the daily MR using
deformable or rigid registration. The treating physician
reviewed the daily MRI and the transferred contours and
manually modiﬁed contours as necessary while the patient
remained on the table. The initial plan was recalculated on
the daily anatomy. Dose volume histograms were
reviewed to evaluate dose to daily anatomy using an
isotoxicity approach. If, by application of the initial plan
to the anatomy of the day, OAR dose constraints were
exceeded or target coverage could be improved, online
plan adaptation was performed via reoptimization with
original beam angles and optimization objectives. All
adapted plans were subject to online quality assurance and
veriﬁed by an independent Monte Carlo dose computation
algorithm prior to treatment delivery while the patient
remained on the table. The reoptimized plan was then
delivered to the daily anatomy.
Treatment gating
Using the real-time planar cine MR images during
treatment delivery, one sagittal plane image is acquired at
4 frames per second. A gating target is chosen (either
tumor or OAR), and a gating boundary is selected at the
discretion of the treating physician and deﬁned on the
volumetric MRI. Prior to the delivery of each fraction, a
sagittal plane was chosen as the reference for gating. The
system then deformed the selected gating target from this
reference frame to each subsequent image acquired during
treatment delivery and compared the resulting contour to
the predeﬁned gating boundary. If the target contour
moved beyond the deﬁned boundary during RT, the beam
automatically turned off. The percentage of target outside
of the deﬁned boundary before the beam turns off can be
speciﬁed by the physician to allow for minor errors in the
deformed contour caused by noise in the MR images and
uncertainties in deformable registration.
Statistical analysis
The data analysis was performed with Excel 2013
(Microsoft Corporation; Redmond, WA).
Results
Patient/treatment characteristics and selection
for magnetic resonance image guided radiation
therapy
Between January 2014 and June 2016, a total of 316
patients were treated with the MR-IGRT system. Disease
sites were divided anatomically as follows: abdomen, 88
Advances in Radiation Oncology: JulyeSeptember 2017 World’s ﬁrst MR-IGRT system 487
patients (28%); breast, 82 patients (26%); head and neck,
17 patients (6%); pelvis, 68 patients (21%); and thorax, 61
patients (19%; Fig 1). Representative MR-IGRT plans for
various disease sites are shown in Figure 2. Patients were
selected for treatment with the MR-IGRT system as
opposed to conventional linear acceleratorebased treat-
ment for a variety of indications, including improved soft
tissue imaging (168 patients [53%]), cine gating (81 pa-
tients [26%]), online ART (67 patients [21%]), or, most
commonly, a combination of these features. Figure 3
depicts the clinical workﬂow and decision process for a
variety of disease sites and scenarios.
Representative clinical decision ﬂowcharts for the
treatment of oligometastatic disease and early stage breast
cancer are shown in Figure 4. Seventy-six patients (24%)
were treated with 3-dimensional conformal RT, 146
(46%) with IMRT, and 94 (30%) with SBRT. A total of
69 patients were treated in a prospective clinical trial.
Nine patients were considered initially for MR-IGRT but
were unable to tolerate the simulation due to claustro-
phobia and/or pain in the treatment position. Approxi-
mately 8 patients per day were treated on the machine
(range, 0-15) with signiﬁcant variation on the basis of the
complexity of the therapy delivered. During these initial
2.5 years, the machine was ofﬂine for 39 business days
(6%) for scheduled source change, software upgrades, and
maintenance.
Online adaptive radiation therapy
Online ART was implemented in September 2014.
Sixty-seven patients (25.7% since the technology became
available) have been treated with online ART. The
adapted treatment course length ranged from 5 fractions
to 28 fractions (median, 5 fractions). A total of 371
fractions were evaluated for daily online ART, and 244 of
these of fractions (66%) were delivered with an adapted
plan. Among the 67 patients who were treated, 26 were
treated in a prospective trial for online-adaptive SBRT
(Trial NCT02264886) and 12 in a dose escalation trial for
inoperable pancreatic cancer (Trial NCT02283372).
Within the subset of trial patients who were treated with
5-fraction SBRT, the incidence of plan adaptation was
84% (81 of 97 fractions). Overall, the subsites treated
with online ART included 18 liver sites (27%), 24
pancreas sites (36%), 5 adrenal sites (7%), 7 central
thorax sites (10%), 8 abdominal lymph node sites (12%),
and 5 “other” cases (7%). An online ART plan for
pancreas SBRT is given in Figure 5.
Cine treatment gating
Sagittal cine treatment gating was ﬁrst implemented in
February 2015. To date, 81 patients (37% since the
technology became available) have undergone treatment
with cine gating. The most common clinical settings were
abdominal (42 patients [52%]) and thoracic (20 patients











Figure 1 Anatomical site of treatment with magnetic reso-
nance image guided radiation therapy.
Figure 2 Example anatomy for commonly treated disease sites, including gross tumor volumes and planning target volumes in blue
and lime and relevant organs-at-risk in purple and orange. Sites include (a) intrahepatic cholangiocarcinoma, (b) early stage breast
cancer, (c) bladder cancer, (d) central thorax malignancy, (e) adrenal metastases, (f) locally advanced pancreatic cancer, (g) post-
operative prostate cancer, and (h) gastric mucosa-associated lymphoid tissue lymphoma.
488 B.W. Fischer-Valuck et al Advances in Radiation Oncology: JulyeSeptember 2017
typically using the tumor plus a median 0.3 cm (range,
0.3-0.5 cm) margin for the gating structure. Figure 6
shows representative examples of cine gating for SBRT
patients. The gating margin around the tumor in both
examples was 0.3 cm, and the average treatment time was
28 minutes (range, 14-36 minutes) with a beam-on time of
93%. When >10% of the tumor volume was tracked
outside of the gating boundary, the beam was automati-
cally turned off with a latency of 246 ms to 527 ms.
Discussion
The world’s ﬁrst commercially available MR-IGRT
system has been successfully used at our institution since
2014. The system features capabilities including onboard
low-ﬁeld MRI, gating based on real-time sagittal cine
MR, and a built-in TPS that is capable of both conven-
tional and online ART. This study sought to describe our
initial clinical experience with integrating MR-IGRT in a
high-volume RT center, characterize the disease sites that
were treated with MR-IGRT, and highlight the technical
capabilities of the system.
Over the past 3 years, approximately 3,500 patients per
year were treated with external beam RT at our facility,
including approximately 290 patients treated with proton
RT and 316 patients treated with MR-IGRT between
January 2014 and June 2016. Since implementing both
proton RT and MR-IGRT, the overall volume of patients
treated at our facility has steadily increased, thus allowing
us to select a highly speciﬁc subgroup of patients who
would likely beneﬁt from MR-IGRT without a decrease in
other treatment modalities in our department. Addition-
ally, the incorporation of the MR-IGRT service into a
high-volume clinic has allowed integration of current
staff, simulation, and dosimetry without changes to other
workﬂows. The group of initial patients and cases for
MR-IGRT was selected based on the improved soft tissue
visualization for setup, reduction of treatment margins,
and/or increased ability to control for any observed
changes during treatment.
The onboard low-ﬁeld MRI offers improved visuali-
zation for selected RT targets and other critical structures
compared with other onboard imaging modalities,
including CBCT.1 The geometric accuracy and soft tissue
deﬁnition of MRI can provide accurate and reproducible
daily localization, leading to potential reduction in treat-
ment margins, and can eliminate the need for ﬁducial
markers. For example, >95% of female patients at our
institution who are candidates for accelerated partial
breast irradiation but unable to undergo high-dose rate
brachytherapy (eg, procedural contraindications) are
treated with MR-IGRT using treatment margins that are
decreased compared with accelerated partial breast irra-
diation on a conventional linac (Fig 4b).8
We previously reported that the mean lumpectomy
cavity displacement during treatment on the cine MR in
the anterior-posterior and superior-inferior directions was
0.6  0.4 mm and 0.6  0.33 mm, respectively.8
Therefore, for these patients, we deﬁned our clinical
GTV as the surgical cavity plus a 1-cm margin (excluding
chest wall and pectoral muscles and 5 mm from skin), and
no additional margin was added for the PTV. This is a
median treatment volume reduction of approximately
52% compared with using a 1-cm PTV margin, which
may result in improved cosmesis.8 Intra- and interfraction
tumor and OAR motion and potential margin reductions
are also currently under investigation in the treatment of
gastric mucosa-associated lymphoid tissue lymphoma and
potentially bladder cancer. We also no longer require
ﬁducial markers to be placed prior to treatment of adrenal
metastases and prostate cancer with the MR-IGRT system
given the excellent daily imaging used for patient set-up.
With a median follow-up of more than 1.5 years, the local
control of patients who were treated for oligometastatic




























Figure 3 Workﬂow of common disease sites and clinical scenarios in which key features of magnetic resonance image guided
radiation therapy are indicated. GU, genitourinary; H&N, head and neck; LAPC, locally advanced pancreatic cancer; liver, primary liver
cancer.
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imaging techniques such as CBCT, the MRI system does
not deliver any additional radiation dose to the patient.
Song et al. measured the average dose of 2 widely used
onboard CBCT systems and found that the average dose
ranged from 0.1 to 3.5 cGy and 1.1 to 8.3 cGy, which
would not be included in the dose calculated by the TPS
and can degrade the delivered plan quality by blurring the
intended isodose lines.9
In addition to the improved setup accuracy and
reduction in unplanned radiation exposure with daily MR
setup imaging, online ART also improves the therapeutic
precision of RT. Previously, the standard method of
addressing interfraction target positioning variation was to
use image guidance for daily patient repositioning on the
basis of rigid anatomical registration using the planning
image and the image acquired just before treatment, with
subsequent delivery of the original plan. To a limited
extent, MR-IGRT alone may manage large interfractional
anatomic shifts and setup errors, but it cannot sufﬁciently
account for known organ deformation, rotation, and
Figure 4 Clinical decision ﬂowchart for using magnetic resonance image guided radiation therapy for (a) unresectable pancreatic/liver
primary or oligometastatic abdominal malignancy and (b) early stage breast cancer.
490 B.W. Fischer-Valuck et al Advances in Radiation Oncology: JulyeSeptember 2017
independent motion between organs, such as within the
abdomen.10 Instead, online ART that uses high-quality
0.35 T volumetric MR images acquired at the start of
each fraction with the MR-IGRT system can fully account
for interfraction volumetric changes in both target vol-
umes and OARs using reoptimization of treatment plans
based on the observed daily anatomy.
The projected beneﬁts of online ART are many and
include margin reduction and an increase in the thera-
peutic window of RT via reduced OAR dose and the
possibility for PTV dose escalation.11-13 A dosimetric
pilot study that was performed with the current MR-IGRT
system demonstrated that simulated online ART
MR-IGRT SBRT would eliminate 100% of unintended
OAR constraint violations that occurred in 61% of
unadapted fractions and permit simultaneous dose esca-
lation.4 ART does require a time investment from the
physician and daily physics support for online quality
assurance of the adaptive plan prior to delivery. However,
as we have previously reported, this is feasible within an
Figure 5 (a) Magnetic resonanceebased, adaptive plan for fraction 1 met all organ-at-risk constraints based on daily set-up anatomy
from fraction 1. (b) Application of the fraction 1 plan to the fraction 2 magnetic resonance image of a patient with a pancreatic tumor
(blue color wash) resulted in a violation of the hard duodenal (green color wash) and small bowel (lime color wash) constraints. (c)
Daily adaptive planning for fraction 2 achieved resolution of the organ-at-risk constraint violation to the duodenum and small bowel
while preserving target volume coverage.
Figure 6 Magnetic resonance real-time cine image with (a, c) the target within the speciﬁed gating margin and the beam turned on and
(b, d) >10% of the target located outside of the speciﬁed gating margin and the beam turned off. Patient 1 had oligometastatic rectal
cancer and underwent stereotactic body radiation therapy to a solitary thorax lesion. Patient 2 had a history of stage IIIA non-small cell
lung cancer with solitary adrenal metastasis and underwent stereotactic body radiation therapy.
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acceptable clinical time frame (median, 26 minutes) for
recontouring, reoptimization, and quality assurance.2
Efforts are also underway to train advanced therapy
personnel to assist in the contouring tasks that account for
the majority of the time required for adaptation. Presently,
we are evaluating the clinical feasibility of online adaptive
MR-guided SBRT for oligometastatic and unresectable
primary malignancies of the abdomen and central thorax
(Trial NCT02264886) and for dose escalation for inop-
erable pancreatic cancer with full dose concurrent
chemotherapy (Trial NCT02283372). These trials use a
fraction-by-fraction isotoxicity approach with planning
prioritization of hard constraints for OARs to minimize
toxicity and maximize the safe deliverable dose to the
target. We have established that there were no instances of
grade 3 or greater toxicities in our patients who were
treated in a phase 1 study of online adaptive SBRT for
abdominal and central thoracic malignancies despite the
use of prescriptions for biological equivalent doses >100.
Our current MR-IGRT system also permits sagittal
planar cine MR gating. The management of intrafraction
motion during RT is a long-standing concern, particularly
within the thorax and abdomen where respiratory motion
and intrafraction physiologic motions challenge technol-
ogy. Prior attempts to track target and OAR motion, such
as the use of 4-dimensional CT planning, internal target
volume construction, and ﬁducial markers are insufﬁcient.
Within the abdomen, internal target volume instability has
been shown to range from 46% to 127% for tumors as
small as 1 cm in diameter.14 A study by Ge et al. revealed
that 4-dimensional CT inadequately represents the daily
motion of abdominal tumors, with a discrepancy noted
between planning CT and daily ﬂuoroscopic video im-
aging in 90% of cases.15 Similarly, for patients who
receive thoracic SBRT, in which treatment precision is
paramount, daily intrafraction motion was found to
exceed the mean target position by >2 mm for 41% of
patients and by >5mm for 7% of patients.16 Even with
ﬁducial use and daily adjustment of gating windows,
studies have shown decreased gating accuracy over the
course of a single treatment session for nearly half of the
delivered fractions in the abdomen.17 In the absence of
real-time tumor imaging, all surrogates for motion require
some additional planning margin to account for these
uncertainties, which that reduce therapeutic precision.
However, with cine MR gating in real time, the GTV it-
self is the gating target, enabling potential reduction of
PTV expansions and eliminating the inherent un-
certainties of motion surrogates. Although there is some
overall system latency in cine imaging processing, our
institution has developed a policy of a 3 mm gating
structure that is expanded from the GTV, which is smaller
than the typical PTV expansion of 5 mm, to minimize the
concern of organ motion beyond the gating target during
that processing lag window. For patients with early stage
non-small cell lung cancer, we selected treatment with
MR-IGRT and cine gating for tumors that remain exces-
sively mobile (>1 cm) after maximal abdominal
compression (eg, tumors near the diaphragm). We have
found that MR gating for such mobile tumors is also more
time efﬁcient compared with other gating systems, and the
tumor can be directly visualized throughout treatment.
Although MR-IGRT has made signiﬁcant strides in
addressing the historic limitations of RT, this novel tech-
nology has limitations of its own. MR-IGRT, particularly
adaptive treatment, requires additional clinical time for
implementation, training, and treatment delivery. An
ongoing phase 1 trial addresses the feasibility of online
adaptive SBRT, and the timing data collected will be used
for process improvement. Additionally, the use of a low-
ﬁeld MR-imaging unit could be considered a limitation of
the current device. However, in our experience, the current,
clinically available low-ﬁeld MR is sufﬁcient for daily
imaging localization, cine gating, and online-adaptive
planning. Diagnostic-quality imaging may have special-
ized applications inMR-IGRT, but its primary applications
comprise initial staging/diagnosis and simulation; it is not
essential for daily use. Other MR-IGRT units under
development offer higher magnet strength and improved
imaging resolution, but their clinical implementation has
been impeded by challenges such as geometric distortion,
dose distribution uncertainty, and undesirable patient
heating.18,19 We acknowledge that both the imaging and
radiation delivery components of MR-IGRT devices will
continue to improve with advancing technology, but we
maintain that the current clinically implemented technol-
ogy is sufﬁcient for broad therapeutic use. Another limi-
tation is the use of 60Co sources. Although the plan quality
between 60Co and linac plans has been shown to be com-
parable, 60Co still has limitations such as less tissue
penetration, greater low dose spread, and longer treatment
times with source decay.7,20 These limitations may be
addressed by future technologies that use MR-linac sys-
tems. In our department, the cobalt radiation delivery
system will be replaced with a 6MV linac while leaving the
current MRI potion of the system in the treatment vault for
use with the linear accelerator.
In addition to the limitations inherent to the MR-IGRT
system, many other challenges were faced during the
implementation of this technology. The machine was
quickly integrated into clinical use and simultaneously
available to all clinical services (eg, breast, thorax,
gastrointestinal, genitourinary). Therefore, each service
had to identify its unique challenges and/or speciﬁc pa-
tients who would beneﬁt the most from the MR-IGRT
technology. As new applications became available (ie,
online adaptation, cine gating), each service also needed to
determine when, how often, and for whom to use these
features. For example, the thorax and gastrointestinal ser-
vices have had speciﬁc challenges in determining when
and how often to adapt hypofractionated treatment cour-
ses. Daily adaptations for extended treatment courses
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(ie, >10 fractions) is likely excessive and burdensome on
the MR-IGRT workﬂow, and trials are in development to
determine the ideal time point to adapt. Speciﬁc margin
sizes and gating windows also remain challenges. These
are questions that are still being answered today, and a
collaboration between multiple institutions that have this
technology has been extremely beneﬁcial and informative.
MR-IGRT has been successfully implemented and pro-
vides unique advantages in the treatment of a variety of
malignancies. Multiple clinical trials are in development to
formally evaluate MR-IGRT in the treatment of various
disease sites using techniques such as SBRT and adaptive
RT. An in silico trial of MR-IGRT with mid-treatment
adaptive planning for hypofractionated stereotactic RT in
centrally located thoracic tumors is ongoing. Additionally,
an analysis of online adaptive SBRT for patients with pros-
tate cancer who use a hydrogel prostate-rectal spacer is
currently underway. Other areas of interest include auto-
segmentation, dose accumulation, motion management, and
the ﬁnancial implications of MR-IGRT. Lastly, a multi-
institutional registry is under development, which will allow
for sharing of clinical outcomes and treatment techniques.
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